Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease: Rationale and Current Evidence

ISSN： 0012-6667

Source： Drugs, Vol.70, Iss.5, 2010-03, pp. : 513-528

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumour Necrosis Factor Modulation for Treatment of Alzheimer's Disease: Rationale and Current Evidence

By Tobinick Edward

CNS Drugs, Vol. 23, Iss. 9, 2009-09 ,pp. : 713-725

Adis International

Access to resources Recommend Favorite

Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies

Current Neuropharmacology, Vol. 7, Iss. 4, 2009-12 ,pp. : 337-342

Bentham Science Publishers

Access to resources Recommend Favorite

Combination Therapy in Alzheimer’s Disease: A Review of Current Evidence

By Schmitt Beate

CNS Drugs, Vol. 18, Iss. 13, 2004-01 ,pp. : 827-844

Adis International

Access to resources Recommend Favorite

Current status and new developments with galantamine in the treatment of Alzheimer’s disease

By Tariot Pierre

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 12, 2001-12 ,pp. : 2027-2049

Informa Healthcare

Access to resources Recommend Favorite

Current strategies for the treatment of Alzheimer’s disease and other tauopathies

By Dickey Chad A Petrucelli Leonard

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 5, 2006-10 ,pp. : 665-676

Informa Healthcare

Access to resources Recommend Favorite